Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).

cited authors

  • Omuro, Antonio Marcilio Padula; DeAngelis, Lisa Marie; Karrison, Theodore; Bovi, Joe A; Rosenblum, Marc; Corn, Benjamin W; Correa, Denise; Wefel, Jeffrey Scott; Aneja, Sanjay; Grommes, Christian; Schaff, Lauren; Waggoner, Steven E; Lallana, Enrico C; Werner-Wasik, Maria; Iwamoto, Fabio; Robinson, Timothy J; Donnelly, Eric; Struve, Timothy; Won, Minhee; Mehta, Minesh P

Digital Object Identifier (DOI)

start page

  • 2501

end page

  • 2501


  • 38


  • 15_suppl